Global
Türkiye
Bangladesh
India
Việt Nam
Indonesia
پاکستان
中国
close

Extractables and Leachables (E&L) Testing

ISO 10993-18

Chemical characterization studies under ISO 10993-18 identify substances that may be released from medical devices. Extractables and leachables (E&L) results are essential inputs for toxicological risk assessment.

  • Required by FDA, EU MDR and other global regulators
  • Applies to polymers, coatings, adhesives, colorants, metals, ceramics
  • Supports overall device risk management
E&L Purpose

Why characterize chemicals for medical devices?

  • Ensures compliance with FDA, EU MDR, global regulators
  • Provides full chemical profile of device materials
  • Supports toxicological risk assessment and biological evaluation
  • Covers VVOC, VOC, SVOC, NVOC and elemental impurities
E&L Testing Process

Hohenstein applies validated analytical methods to characterize device materials.

  • Sample preparation (ISO 10993-12)
  • VOC screening in aqueous extracts (GC-MS)
  • SVOC screening in aqueous, semi-polar and non-polar extracts (GC-MS)
  • NVOC screening in aqueous, semi-polar and non-polar extracts (HPLC-qTOF)
  • Elemental impurity screening in aqueous extracts (ICP-MS)
  • VVOC and VOC screening by thermal desorption (in emission chamber)
Extractables vs Leachables

What is the difference between Extractables & Leachables?

  • Extractables testing uses strong solvents, elevated temperatures and extended extraction times to create exaggerated, worst-case conditions. These studies:
    • Identify and quantify compounds that could potentially extract from a device
    • Reveal more compounds than would typically appear under clinical use
  • Leachables testing uses simulated-use conditions (e.g., artificial urine) to reveal a more realistic patient exposure

Used together with a toxicological risk assessment (TRA), these studies help determine if further safety testing is needed.

Why Hohenstein Medical?

  • Testing performed in ISO/IEC 17025–accredited, GLP-certified laboratory
  • Decades of material chemistry and biocompatibility expertise
  • US-based team with direct coordination to FDA and EU MDR requirements
  • Integrated support with broader ISO 10993 biological evaluation services
  • Customized study designs for unique materials, device types and risk profiles
Contact
Ben Mead
Managing Director
Hohenstein Americas